Lexeo Therapeutics (LXEO) Research & Development (2022 - 2026)

Lexeo Therapeutics has reported Research & Development for 5 years, with the latest figure at $15.7 million in Q1 2026.

• Quarterly Research & Development fell 8.55% year-over-year to $15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.1 million (down 38.93% YoY) and the FY2025 annual result came in at $63.8 million, down 13.89% from the prior year.
• Research & Development held at $15.7 million in Q1 2026 per LXEO's latest filing, from $15.7 million in the prior quarter.
• Over five years, Research & Development peaked at $23.4 million in Q3 2024 and troughed at -$44.9 million in Q4 2023.
• A 5-year average of $11.7 million and a median of $15.7 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2024: Research & Development sank 494.48% in 2023, then jumped 140.89% in 2024.
• Over 5 years, Research & Development stood at $11.4 million in 2022, then tumbled by 494.48% to -$44.9 million in 2023, then surged by 140.89% to $18.4 million in 2024, then slipped by 14.54% to $15.7 million in 2025, then gained by 0.05% to $15.7 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $15.7 million, $15.7 million, and $14.7 million for Q1 2026, Q3 2025, and Q2 2025 respectively.